Correspondence 0001683168-26-003939 from Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: May 14, 2026 · CIK: 0001402328 · Accession: 0001683168-26-003939
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295800
Letter
RE: SUNSHINE BIOPHARMA INC. (CIK: 0001402328)
May 14, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement No. 333-295800 on Form S-1 (the "Registration Statement")
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Securities Act" ), Aegis Capital Corp. hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time, May 18, 2026, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution.
The undersigned has complied and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
By: AEGIS CAPITAL CORP.
By: /s/ Robert Eide
Name: Robert Eide
Title: Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm May 14, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: SUNSHINE BIOPHARMA INC. (CIK: 0001402328) Registration Statement No. 333-295800 on Form S-1 (the "Registration Statement") Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the "Securities Act" ), Aegis Capital Corp. hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time, May 18, 2026, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many electronic copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution. The undersigned has complied and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. By: AEGIS CAPITAL CORP. By: /s/ Robert Eide Name: Robert Eide Title: Chief Executive Officer